U.S. Markets closed

Myriad Genetics, BioMarin advance PARP collaboration into Phase 3

Myriad Genetics (MYGN) announced that BioMarin Pharmaceutical (BMRN) will use Myriad's BRACAnalysis test in connection with its pivotal Phase 3 clinical studies for BMN 673. BMN 673 is a novel, orally-active PARP inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad will collaborate with BioMarin to deliver BRAC testing for its pivotal clinical studies. As required by the FDA, Myriad also submitted an Investigational Device Exemption to the FDA that will allow for BRACAnalysis testing to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program. Additional terms of the deal were not disclosed.